{"pmid":32299796,"title":"Antirheumatic agents in covid-19: is IL-6 the right target?","text":["Antirheumatic agents in covid-19: is IL-6 the right target?","Ann Rheum Dis","Capecchi, Pier Leopoldo","Lazzerini, Pietro Enea","Volterrani, Luca","Mazzei, Maria Antonietta","Rossetti, Barbara","Zanelli, Giacomo","Bennett, David","Bargagli, Elena","Franchi, Federico","Cameli, Matteo","Valente, Serafina","Cantarini, Luca","Frediani, Bruno","32299796"],"journal":"Ann Rheum Dis","authors":["Capecchi, Pier Leopoldo","Lazzerini, Pietro Enea","Volterrani, Luca","Mazzei, Maria Antonietta","Rossetti, Barbara","Zanelli, Giacomo","Bennett, David","Bargagli, Elena","Franchi, Federico","Cameli, Matteo","Valente, Serafina","Cantarini, Luca","Frediani, Bruno"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32299796","week":"202016|Apr 13 - Apr 19","doi":"10.1136/annrheumdis-2020-217523","keywords":["antirheumatic agents","cardiovascular diseases","inflammation","patient care team"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1664357978607714304,"score":8.233237,"similar":[{"pmid":32295789,"title":"Role of immunosuppressive therapy in rheumatic diseases concurrent with covid-19.","text":["Role of immunosuppressive therapy in rheumatic diseases concurrent with covid-19.","Ann Rheum Dis","Lu, Chenyang","Li, Shasha","Liu, Yi","32295789"],"journal":"Ann Rheum Dis","authors":["Lu, Chenyang","Li, Shasha","Liu, Yi"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32295789","week":"202016|Apr 13 - Apr 19","doi":"10.1136/annrheumdis-2020-217460","keywords":["antirheumatic agents","cytokines","inflammation"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664266651241021440,"score":106.235344},{"pmid":32266708,"title":"Renin-Angiotensin System Inhibition in Cardiovascular Patients at the Time of COVID19: Much Ado for Nothing? A Statement of Activity from the Directors of the Board and the Scientific Directors of the Italian Society of Hypertension.","text":["Renin-Angiotensin System Inhibition in Cardiovascular Patients at the Time of COVID19: Much Ado for Nothing? A Statement of Activity from the Directors of the Board and the Scientific Directors of the Italian Society of Hypertension.","Cardiovascular diseases, in particular hypertension, as well as the cardiovascular treatment with Renin-Angiotensin System inhibitors such as Angiotensin Converting Enzyme (ACE) inhibitors and Angiotensin Receptor Blockers (ARBs), are claimed once again as mechanisms of Severe Acute Respiratory Syndrome (SARS) during the COVID-19 outbreak due to Cov-2 epidemics. In vitro studies are available to support the eventual role of ACE inhibitors and ARBs in both the promotion and antagonism of the disease. The available literature, indeed, presents contrasting results, all concentrated in experimental models. Evidence in humans is lacking that those mechanisms are actually occurring in the present COVID-19 outbreak. Here we present the reasoned statement of the Italian Society of Hypertension to maintain ongoing antihypertensive treatments. Furthermore, the Italian Society of Hypertension presents its own initiative to investigate the issue using an online questionnaire to collect relevant data in human disease.","High Blood Press Cardiovasc Prev","Iaccarino, Guido","Borghi, Claudio","Cicero, Arrigo F G","Ferri, Claudio","Minuz, Pietro","Muiesan, Maria Lorenza","Mulatero, Paolo","Mule, Giuseppe","Pucci, Giacomo","Salvetti, Massimo","Savoia, Carmine","Sechi, Leonardo Alberto","Volpe, Massimo","Grassi, Guido","32266708"],"abstract":["Cardiovascular diseases, in particular hypertension, as well as the cardiovascular treatment with Renin-Angiotensin System inhibitors such as Angiotensin Converting Enzyme (ACE) inhibitors and Angiotensin Receptor Blockers (ARBs), are claimed once again as mechanisms of Severe Acute Respiratory Syndrome (SARS) during the COVID-19 outbreak due to Cov-2 epidemics. In vitro studies are available to support the eventual role of ACE inhibitors and ARBs in both the promotion and antagonism of the disease. The available literature, indeed, presents contrasting results, all concentrated in experimental models. Evidence in humans is lacking that those mechanisms are actually occurring in the present COVID-19 outbreak. Here we present the reasoned statement of the Italian Society of Hypertension to maintain ongoing antihypertensive treatments. Furthermore, the Italian Society of Hypertension presents its own initiative to investigate the issue using an online questionnaire to collect relevant data in human disease."],"journal":"High Blood Press Cardiovasc Prev","authors":["Iaccarino, Guido","Borghi, Claudio","Cicero, Arrigo F G","Ferri, Claudio","Minuz, Pietro","Muiesan, Maria Lorenza","Mulatero, Paolo","Mule, Giuseppe","Pucci, Giacomo","Salvetti, Massimo","Savoia, Carmine","Sechi, Leonardo Alberto","Volpe, Massimo","Grassi, Guido"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32266708","week":"202015|Apr 06 - Apr 12","doi":"10.1007/s40292-020-00380-3","keywords":["COVID-19","cardiovascular diseases","hypertension","infection","outcomes"],"source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"_version_":1663609715836321793,"score":96.721954},{"pmid":32241793,"title":"Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies.","text":["Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies.","Ann Rheum Dis","Monti, Sara","Balduzzi, Silvia","Delvino, Paolo","Bellis, Elisa","Quadrelli, Verdiana Serena","Montecucco, Carlomaurizio","32241793"],"journal":"Ann Rheum Dis","authors":["Monti, Sara","Balduzzi, Silvia","Delvino, Paolo","Bellis, Elisa","Quadrelli, Verdiana Serena","Montecucco, Carlomaurizio"],"date":"2020-04-04T11:00:00Z","year":2020,"_id":"32241793","week":"202014|Mar 30 - Apr 05","doi":"10.1136/annrheumdis-2020-217424","keywords":["antirheumatic agents","arthritis, rheumatoid","biological therapy","spondylitis, ankylosing"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1663352135795867648,"score":81.6696},{"pmid":32303609,"title":"Covid-19 and immunomodulation in IBD.","text":["Covid-19 and immunomodulation in IBD.","The current coronavirus pandemic is an ongoing global health crisis due to covid-19, caused by severe acute respiratory syndrome coronavirus 2. Although covid-19 leads to little or mild flu-like symptoms in the majority of affected patients, the disease may cause severe, frequently lethal complications such as progressive pneumonia, acute respiratory distress syndrome and organ failure driven by hyperinflammation and a cytokine storm syndrome. This situation causes various major challenges for gastroenterology. In the context of IBD, several key questions arise. For instance, it is an important question to understand whether patients with IBD (eg, due to intestinal ACE2 expression) might be particularly susceptible to covid-19 and the cytokine release syndrome associated with lung injury and fatal outcomes. Another highly relevant question is how to deal with immunosuppression and immunomodulation during the current pandemic in patients with IBD and whether immunosuppression affects the progress of covid-19. Here, the current understanding of the pathophysiology of covid-19 is reviewed with special reference to immune cell activation. Moreover, the potential implications of these new insights for immunomodulation and biological therapy in IBD are discussed.","Gut","Neurath, Markus F","32303609"],"abstract":["The current coronavirus pandemic is an ongoing global health crisis due to covid-19, caused by severe acute respiratory syndrome coronavirus 2. Although covid-19 leads to little or mild flu-like symptoms in the majority of affected patients, the disease may cause severe, frequently lethal complications such as progressive pneumonia, acute respiratory distress syndrome and organ failure driven by hyperinflammation and a cytokine storm syndrome. This situation causes various major challenges for gastroenterology. In the context of IBD, several key questions arise. For instance, it is an important question to understand whether patients with IBD (eg, due to intestinal ACE2 expression) might be particularly susceptible to covid-19 and the cytokine release syndrome associated with lung injury and fatal outcomes. Another highly relevant question is how to deal with immunosuppression and immunomodulation during the current pandemic in patients with IBD and whether immunosuppression affects the progress of covid-19. Here, the current understanding of the pathophysiology of covid-19 is reviewed with special reference to immune cell activation. Moreover, the potential implications of these new insights for immunomodulation and biological therapy in IBD are discussed."],"journal":"Gut","authors":["Neurath, Markus F"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32303609","week":"202016|Apr 13 - Apr 19","doi":"10.1136/gutjnl-2020-321269","keywords":["cytokines","inflammation","inflammatory bowel disease"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1664431720454160385,"score":75.592896},{"pmid":32299202,"title":"COVID-19, immune system response, hyperinflammation and repurposing anti-rheumatic drugs.","text":["COVID-19, immune system response, hyperinflammation and repurposing anti-rheumatic drugs.","In the Wuhan province of China, in December 2019, the novel Coronavirus 2019 (COVID-19) has caused a severe involvement of the lower respiratory tract leading to an acute respiratory syndrome. Subsequently, coronavirus 2 (SARS-CoV-2) provoked a pandemic which is considered a life-threatening disease. The SARS-CoV-2, a family member of betacoronaviruses, possesses single single-stranded positive-sense RNA with typical structural proteins, involving the envelope, membrane, nucleocapsid and spike proteins that are responsible for the viral infectivity, and nonstructural proteins. The effectual host immune response including innate and adaptive immunity against SARS-Cov-2 seems crucial to control and resolve the viral infection. However, the severity and outcome of the COVID-19 might be associated with the excessive production of proinflammatory cytokines ?cytokine storm? leading to an acute respiratory distress syndrome. Regretfully, the exact pathophysiology and treatment, especially for the severe disease of COVID-19, is still uncertain. The results of preliminary studies have shown that immune-modulatory or immune-suppressive treatments such as hydroxychloroquine, interleukin (IL)-6 and IL-1 antagonists, commonly used in rheumatology, might be considered as treatment choices for COVID-19, particularly in severe lung disease. In this review, to better gain information about appropriate anti-inflammatory treatments, mostly used in rheumatology for COVID-19, we have focused the attention on the structural features of SARS-CoV-2, the host immune response against SARS-CoV-2 and its association with the cytokine storm.","Turk J Med Sci","Tufan, Abdurrahman","Avanoglu Guler, Aslihan","Matucci-Cerinic, Marco","32299202"],"abstract":["In the Wuhan province of China, in December 2019, the novel Coronavirus 2019 (COVID-19) has caused a severe involvement of the lower respiratory tract leading to an acute respiratory syndrome. Subsequently, coronavirus 2 (SARS-CoV-2) provoked a pandemic which is considered a life-threatening disease. The SARS-CoV-2, a family member of betacoronaviruses, possesses single single-stranded positive-sense RNA with typical structural proteins, involving the envelope, membrane, nucleocapsid and spike proteins that are responsible for the viral infectivity, and nonstructural proteins. The effectual host immune response including innate and adaptive immunity against SARS-Cov-2 seems crucial to control and resolve the viral infection. However, the severity and outcome of the COVID-19 might be associated with the excessive production of proinflammatory cytokines ?cytokine storm? leading to an acute respiratory distress syndrome. Regretfully, the exact pathophysiology and treatment, especially for the severe disease of COVID-19, is still uncertain. The results of preliminary studies have shown that immune-modulatory or immune-suppressive treatments such as hydroxychloroquine, interleukin (IL)-6 and IL-1 antagonists, commonly used in rheumatology, might be considered as treatment choices for COVID-19, particularly in severe lung disease. In this review, to better gain information about appropriate anti-inflammatory treatments, mostly used in rheumatology for COVID-19, we have focused the attention on the structural features of SARS-CoV-2, the host immune response against SARS-CoV-2 and its association with the cytokine storm."],"journal":"Turk J Med Sci","authors":["Tufan, Abdurrahman","Avanoglu Guler, Aslihan","Matucci-Cerinic, Marco"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32299202","week":"202016|Apr 13 - Apr 19","doi":"10.3906/sag-2004-168","keywords":["covid-19","anti-inflammatory","cytokine storm","inflammation","rheumatology","treatment"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Hydroxychloroquine"],"_version_":1664357978499710977,"score":75.45861}]}